Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (foveolar cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: ensituximab, yttrium y 90 clivatuzumab tetraxetan, clivatuzumab tetraxetan | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 6 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5076
Sealed predictions
- MUC5AC in dopamine neurons, braak-0.35 (p 0.362) → -0.71 (p 0.031)receipt 5083
Swarm cases
receipt 5083: MUC5AC in dopamine neurons, braak
- power
- full sample -0.48 (p 0.043, n 18), 95% CI -0.77 to -0.02. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.48 (p 0.043, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.60 (p 0.0083, n 18). not the mix.
- skeptic
- leave-one-out range -0.63 to -0.41, sign flips 0; without severely affected donors -0.48 (p 0.043, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MUC5AC in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts